<!DOCTYPE html>
<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/
-->
<!--[if lt IE 7]>
<html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en">
<![endif]-->
<!--[if IE 7]>
<html class="no-js lt-ie9 lt-ie8" lang="en">
<![endif]-->
<!--[if IE 8]>
<html class="no-js lt-ie9" lang="en">
<![endif]-->
<!--[if gt IE 8]>
<!-->
<html class="no-js" lang="en">
<!--<![endif]-->

<head>
    <meta charset="utf-8" />
    <!-- Set the viewport width to device width for mobile -->
    <meta name="viewport" content="width=device-width" />
    <title>
        PracticeUpdate : Expert Opinion Item
    </title>
    <link rel="stylesheet" href="assets/css/app.css">
    <link rel="stylesheet" href="assets/css/font-awesome.css">
    <link rel="stylesheet" href="assets/css/fc-webicons.css">
    <link rel="stylesheet" href="assets/css/foundation-icons-general.css">
    <script src="assets/js/foundation/modernizr.foundation.js">
    </script>
    <!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js">
        </script>
    <![endif]-->
</head>

<body id="page" class="update off-canvas slide-nav expert-opinion-item logged-out">
    <div class="widget ad">
        <div id="leaderboard" class="Breast ad-container">
            <div class="ad-title">
                <span class="ad-title-text">
                    advertisement
                </span>
            </div>
            <!--/.ad-title-->
            <div id="leaderboardcontent" class="ad-content">
            </div>
            <!--.ad-content-->
        </div>
        <!--/#leaderboard.ad-container-->
    </div>
    <!--/.widget.ad-->
    <div class="page-header">
    </div>
    <!--/.page-header-->
    <div class="page-content">
        <section role="main">
            <div class="single-item-container">
                <article class="type-expert-opinion single-item">
                    <!-- info taken from: http://oncologystat.com/viewpoints/seminal_articles/Seminal_Articles_Germ_Cell_Tumors.html
                    -->
                    <div class="item-header-container">
                        <header class="item-header">
                            <div class="flag-container">
                                <span class="flag featured">
                                    <i class="icon-bolt">
                                    </i>
                                    featured
                                </span>
                                <span class="flag story-of-the-week">
                                    <i class="icon-bolt">
                                    </i>
                                    story of the week
                                </span>
                            </div>
                            <div class="meta pub-meta">
                                <span class="item-type">
                                    Seminal Article
                                </span>
                                <span class="item-pub-date">
                                    <time datetime="12-12-19">
                                        December 19, 2012
                                </span>
                            </div>
                            <hgroup class="item-title-container">
                                <h1 class="item-title">
                                    Seminal Articles—Breast Cancer
                                </h1>
                                <p class="item-citation">
                                    <!-- {{source.citation}} -->
                                    2012 Mar 6, Clifford Hudis, MD, Editor: Patrick Morris, MD, Editor: Ayca Gucalp, MD
                                </p>
                            </hgroup>
                            <!-- /.item-title-container -->
                        </header>
                    </div>
                    <!--/.item-header-container-->
                    <div class="item-content-container">
                        <div class="item-content">
                            <div class="item-content-section">
                                <section class="seminal-article-body">
                                    <div class="seminal-article-body-container">
                                        <div class="source-container">
                                            <div class="vcard">
                                            </div>
                                            <!--/.vcard-->
                                        </div>
                                        <!--/.source-container-->
                                        <p>Based on our expert's review, here are the must-read articles for every oncologist about breast cancer.</p><p><strong>Gene Expression Profile</strong></p><p>1. Paik S, T Gong, Shak S, et al. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor&ndash;Positive Breast Cancer. <a target="_blank" href="http://jco.ascopubs.org/content/24/23/3726.full.pdf+html">J Clin Oncol. August 10, 2006; 24(23):3726-3734</a>.</p><p>2. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. <a target="_blank" href="http://download.thelancet.com/pdfs/journals/lanonc/PIIS1470204509703146.pdf?id=5bbe37e152166496:-210518de:13318bc4cd1:-65571318970711723">Lancet Oncol. January 2010; 11(1):55-65</a>. Elsevier, <strong>Free</strong></p><p><strong>Prevention/DCIS</strong></p><p>3. Wapnir IL, Dignam JJ, Fisher B, et al. Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS. <a target="_blank" href="http://jnci.oxfordjournals.org/content/early/2011/03/11/jnci.djr027.abstract">J Natl Cancer Inst. Published on-line March 11, 2011</a>. <strong>Free</strong></p><p>4. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for Breast-Cancer Prevention in Postmenopausal Women. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1103507">N Engl J Med. June 23, 2011; 364(25):2381-2391</a>. <strong>Free</strong></p><p><strong>Local Therapy</strong></p><p>5. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa040587">N Engl J Med. September 2, 2004; 351:971-977</a>. <strong>Free</strong></p><p>6. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. <a target="_blank" href="http://jama.ama-assn.org/content/305/6/569.full.pdf+html?sid=01c0d098-d485-4e98-b1c6-c67fdd217cc2">JAMA. 2011; 305(6):569-575</a>.</p><p><strong>Locally Advanced Breast Cancer/Neoadjuvant Chemotherapy</strong></p><p>7. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. <a target="_blank" href="http://jco.ascopubs.org/content/15/7/2483.abstract">J Clin Oncol. July 1, 1997; 15(7):2483-2493</a>.</p><p>8. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27. <a target="_blank" href="http://jco.ascopubs.org/content/21/22/4165.abstract?sid=c130d513-850f-4c60-aa06-55ea31d97575">J Clin Oncol. November, 2003; 21(22):4165-4174</a>.</p><p><strong>Chemotherapy: Adjuvant</strong></p><p>9. Bonadonna G, Valaqussa P, Moliterni A, et al. Adjuvant, Cyclophosphamide, Methotrexate and Fluorouracil in node positive breast cancer: The Results of 20 Years of Follow-up. <a target="_blank" href="http://www.nejm.org/doi/pdf/10.1056/NEJM199504063321401">N Engl J Med. April 6, 1995; 332(14):901-906</a>. <strong>Free</strong></p><p>10. Citron ML, Berry DA, Cirrincione C, et al. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. <a target="_blank" href="http://jco.ascopubs.org/content/21/8/1431.long">J Clin Oncol. April 15, 2003; 21(8):1431-1439</a>.</p><p>11. Henderson IC, Berry DA, Demetri GD, et al. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. <a target="_blank" href="http://jco.ascopubs.org/content/21/6/976.long">J Clin Oncol. March 15, 2003; 21(6):976-83</a>.</p><p>12. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. <a target="_blank" href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)66544-0/fulltext?_eventId=login">Lancet. May 14, 2005; 365(9472):1687-1717</a>. Elsevier</p><p>13. Jones SE, Savin MA, Holmes FA, et al. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. <a target="_blank" href="http://jco.ascopubs.org/content/24/34/5381.long">J Clin Oncol. December 1, 2006; 24(34)5381-5387</a>.</p><p>14. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa0707056">N Engl J Med. April 17, 2008; 358(16):1663-1671</a>. <strong>Free</strong></p><p>15. Muss HB, Berry DA, Cirrincione C, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa0810266">N Engl J Med. May 14, 2009; 360(20):2055-2065</a>. <strong>Free</strong></p><p><strong>HER2-Positive Disease: Adjuvant</strong></p><p>16. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa052122">N Engl J Med. October 20, 2005; 353(16):1673-1684</a>. <strong>Free</strong></p><p>17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa052306">N Engl J Med. October 20, 2005; 353(16):1659-1672</a>. <strong>Free</strong></p><p><strong>Hormone Therapy: Adjuvant</strong></p><p>18. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. <a target="_blank" href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)09088-8/fulltext">Lancet. July 22, 2002; 59(9324):2131-2139</a>. Elsevier</p><p>19. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa040331">N Engl J Med. March 11, 2004; 50(11):1081-1092</a>. <strong>Free</strong></p><p>20. Breast International Group (BIG) I-98 Collaborative Group: Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa052258">N Engl J Med. December 29, 2005; 353(26):2747-2757</a>. <strong>Free</strong></p><p>21. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. <a target="_blank" href="http://jnci.oxfordjournals.org/content/97/17/1262.full">J Natl Cancer Inst. September 7, 2005; 97(17):1262-1271</a>. <strong>Free</strong></p><p>22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Davies C, Godwin J, Gray R, et al. (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. <a target="_blank" href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60993-8/abstract">Lancet. August 27, 2011; 378(9793):771-784</a>. Elsevier, <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163848/?tool=pubmed"><strong>Free</strong></a></p><p><strong>Chemotherapy: Metastatic Disease</strong></p><p>23. O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. <a target="_blank" href="http://jco.ascopubs.org/content/20/12/2812.long">J Clin Oncol. June 15, 2002; 20(12):2812-2823</a>.</p><p>24. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). <a target="_blank" href="http://jco.ascopubs.org/content/21/4/588.long">J Clin Oncol. February 15, 2003; 21(4):588-592</a>.</p><p>25. Gradishar WJ, Tjulandin S , Davidson N , et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil based paclitaxel in women with breast cancer. <a target="_blank" href="http://jco.ascopubs.org/content/23/31/7794.long">J Clin Oncol. November 1, 2005; 23(31):7794-7803</a>.</p><p>26. Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. <a target="_blank" href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60070-6/fulltext">Lancet. March 12, 2011; 377(9769):914-923</a>. Elsevier</p><p>27. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. <a target="_blank" href="http://jco.ascopubs.org/content/26/10/1642.long">J Clin Oncol. April 1, 2008; 26(10):1642-1649</a>.</p><p>28. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. <a target="_blank" href="http://jco.ascopubs.org/content/26/24/3950.long">J Clin Oncol. August 20, 2008; 26(24):3950-3957</a>.</p><p><strong>Hormone Therapy: Metastatic Disease</strong></p><p>29. Chia S, Gradishar WJ, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. <a target="_blank" href="http://jco.ascopubs.org/content/26/10/1664.long">J Clin Oncol. April 1, 2008; 26(10):1664-1670</a>.</p><p><strong>HER2-Positive Disease: Metastatic Disease</strong></p><p>30. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJM200103153441101">N Engl J Med. March 15, 2001; 344(11):783-792</a>. <strong>Free</strong></p><p>31. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa064320">N Engl J Med. December 28, 2006; 355(26):2733-2743</a>. <strong>Free</strong></p><p>32. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. <a target="_blank" href="http://jco.ascopubs.org/content/28/7/1124.long">J Clin Oncol. March 1, 2010; 28(7):1124-1130</a>.</p><p><strong>HER2-Negative: Bevacizumab: Metastatic Disease</strong></p><p>33. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa072113">N Engl J Med. December 27, 2007; 357(26):2666-2676</a>. <strong>Free</strong></p><p>34. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. <a target="_blank" href="http://jco.ascopubs.org/content/28/20/3239.long">J Clin Oncol. July 10, 2010; 28(20):3239-3247</a>.</p><p></p>
                                    </div>
                                    <!--/.seminal-article-body-container -->
                                </section>
                                <!-- /.seminal-article-body -->
                            </div>
                            <!-- ./item-content-section -->
                        </div>
                        <!-- ./item-content -->
                    </div>
                    <!-- /.item-conten-container -->
                    <hr />
                    <footer class="copyright item-footer">
                        <img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"
                        />
                        <p>
                            Copyright &copy; 2012 Elsevier
                        </p>
                    </footer>
            </div>
            <!--/.item-container-->
            <div class="recommended">
                <div class="recent">
                </div>
                <!--/.recent-->
                <div class="ad">
                    <img src="http://placehold.it/300x250" align="ad" title="ad" />
                </div>
            </div>
            <!--/.recommended-->
        </section>
        <!--/[role="main"]-->
        <section id="sidebar" role="complementary">
            <div class="dashboard">
                <div class="panel cta register">
                    <p>
                        <!-- Meet Our Experts -->
                        Become a member to customize this page.
                        <p>
                            <a class="button" href="#action-register">Register for free</a>
                </div>
                <!--/.panel.cta.register-->
                <div class="component user-console">
                </div>
                <!--/.component.user-console-->
                <div class="component user-topic">
                </div>
                <!--/.component.user-topic-->
                <div class="component topic-spotlight">
                </div>
                <!--/.component.topic-spotlight-->
                <div class="panel">
                    <img src="http://placehold.it/200x200" />
                    <p>
                        <!-- Meet Our Experts -->
                        Meet our Advisory and Editorial Boards comprised of physician editors
                        and world-renowned experts.
                        <p>
                </div>
            </div>
            <!--/.sidebar-->
        </section>
        <!--/.[role="complimentary"]-->
    </div>
    <!--/.page-content-->
	<div class="page-footer-container">
    <footer class="page-footer">
    </footer>
	</div><!-- /.page-footer-container -->
    <!-- /.page-footer -->
    <!-- Included JS Files (Uncompressed) -->
    <script src="assets/js/foundation/jquery.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.accordion.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.alerts.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.buttons.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.forms.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.navigation.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.orbit.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.reveal.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tabs.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tooltips.js">
    </script>
    <script src="assets/js/foundation/jquery.placeholder.js">
    </script>
    <script src="assets/js/foundation/app.js">
    </script>
    <script src="assets/js/foundation/jquery.offcanvas.js">
    </script>
    <script src="assets/js/mustache.js">
    </script>
    <!-- Mustache - homepage feed template -->
    <script>
                    	<!--
	Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
	    $.get('assets/mustache/feed-item.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.stream-container').html(html);
	    });

	});

	<!--
	Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
	    $.get('assets/mustache/recent.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.recent').html(html);
	    });

	});

	<!--
	Mustache - homepage user - console template -->
	$.getJSON('content/json/user-console.json', function(data) {
	    $.get('assets/mustache/user-console.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-console').html(html);
	    });
	});

	<!--
	Mustache - homepage user - topic template -->
	$.getJSON('content/json/user-topic.json', function(data) {
	    $.get('assets/mustache/user-topic.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-topic').html(html);
	    });
	});

	<!--
	Mustache - homepage topic - spotlight template -->
	$.getJSON('content/json/topic-spotlight.json', function(data) {
	    $.get('assets/mustache/topic-spotlight.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.topic-spotlight').html(html);
	    });
	});
</script>
</body>

</html>